EMG
EIGR

Ellington Management Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ellington Management Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-470
Closed -$96K – 472
2020
Q1 		$96K Buy
+470
New +$150K 0.02% 496

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Ellington Management Group's EIGR Position: Q2 2020 in Review

Ellington Management Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 470 shares — an estimated $96K sold.

Ellington Management Group first reported a position in EIGR in Q1 2020 and held it in 1 quarter. The position peaked at $96K in Q1 2020. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

  • Ellington Management Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 470 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $96K.
  • Ellington Management Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Ellington Management Group's Eiger BioPharmaceuticals, Inc. position peaked at $96K in Q1 2020.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.